SCHEMBL30347641

SCHEMBL30347641

Cc1nc2ccc(-c3c[nH]c4nc(Nc5ccc(N6CCN(C)CC6)nc5)ncc34)nc2n1CC(F)F

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 2/20 0.45
CLK2 P49760 1/20 0.45
CLK3 P49761 1/20 0.45
JAK3 P52333 5/20 0.40
WEE1 P30291 4/20 0.40
ACVR1 Q04771 1/20 0.38
EGFR P00533 1/20 0.38
CDK9 P50750 2/20 0.38
DYRK2 Q92630 1/20 0.38
TDO2 P48775 1/20 0.38
JAK2 O60674 3/20 0.37
JAK1 P23458 2/20 0.37
CYP3A4 P08684 1/20 0.37
BTK Q06187 1/20 0.37
CTSC P53634 1/20 0.37
CDK2 P24941 3/20 0.37
CDK1 P06493 1/20 0.37
CCNB1 P14635 1/20 0.37
CCNE1 P24864 1/20 0.37
FLT3 P36888 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25204969 1.00 DYRK1A (0.45) DYRK1ACLK2CLK3JAK3WEE1
SCHEMBL25208280 0.90 DYRK1A (0.58) DYRK1ACLK2CLK3WEE1CDK9
SCHEMBL30346544 0.90 DYRK1A (0.58) DYRK1ACLK2CLK3WEE1CDK9
SCHEMBL30347865 0.89 DYRK1A (0.38) DYRK1ACLK2CLK3CDK9DYRK2
SCHEMBL25195470 0.89 DYRK1A (0.38) DYRK1ACLK2CLK3CDK9DYRK2
SCHEMBL25204892 0.87 CDK2 (0.53) DYRK1ACLK2CLK3JAK3WEE1
SCHEMBL30346927 0.87 CDK2 (0.53) DYRK1ACLK2CLK3JAK3WEE1
SCHEMBL25156872 0.86 CLK2 (0.47) DYRK1ACLK2CLK3JAK3WEE1
SCHEMBL30348331 0.86 CLK2 (0.47) DYRK1ACLK2CLK3JAK3WEE1
SCHEMBL25157669 0.82 DYRK1A (0.43) DYRK1ACLK2CLK3EGFRCDK9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250129104-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF TENARX, INC. 2025-04-24 US claimed
EP-4415818-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AS DYRK1A INHIBITORS BioSplice Therapeutics, Inc. (US) 2024-08-21 EP claimed
US-20230167133-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF VICKERS VENTURE FUND VI PTE. LTD. (SG) 2023-06-01 US claimed
WO-2023064361-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AS DYRK1A INHIBITORS BIOSPLICE THERAPEUTICS, INC. (US) 2023-04-20 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230167133-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF DYRK1A, DYRK1B, DYRK2 DYRK1A 1/4885CLK2 466/4885CLK3 1147/4885
US-20250129104-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF DYRK1A, DYRK1B, DYRK2 DYRK1A 1/4885CLK2 466/4885CLK3 1147/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.